ACS Medicinal Chemistry Letters p. 647 - 652 (2021)
Update date:2022-08-16
Topics:
Deng, Wuqing
Chen, Xiaojuan
Jiang, Kaili
Song, Xiaojuan
Huang, Minhao
Tu, Zheng-Chao
Zhang, Zhang
Lin, Xiaojing
Ortega, Raquel
Patterson, Adam V.
Smaill, Jeff B.
Ding, Ke
Chen, Suming
Chen, Yongheng
Lu, Xiaoyun
Covalent kinase inhibitors are rapidly emerging as a class of therapeutics with clinical benefits. Herein we report a series of selective 2-aminopyrimidine-based fibroblast growth factor receptor 4 (FGFR4) inhibitors exploring different types of cysteine-
View MoreShanghai Yuanding Chem. Sci. & Tech. Co., Ltd.
website:http://www.shydtec.com
Contact:86-21-57721279
Address:Science and Technology Park, Songjiang District, Shanghai, China
Jiangsu Allyrise Pharmaceutical Co., Ltd.(expird)
Contact:+86-523-86818997
Address:Taizhou,Jiangsu Province,CHINA
Liaoyang hengye Chemical Co., Ltd.
Contact:86-419-5850866
Address:North Old Xiaoxiao Road,Yantai District, Dengta, Liaoyang, Liaoning, China
Shanghai Kangxin Chemical Co., Ltd
Contact:+86 21 60717227
Address:118,Ganbai Village,Waigang Town,Jiading District,Shanghai
HANGZHOU PANYU CHEMICAL CO.,LIMITED
Contact:+86-571-86578491
Address:Rm 605, NO.1870 Binsheng Road,Binjiang Dist, Hangzhou, China
Doi:10.1039/c5ra14852a
(2015)Doi:10.1021/acs.jmedchem.5b01357
(2016)Doi:10.1002/ejoc.201200776
(2012)Doi:10.1016/j.ejmech.2015.10.035
(2015)Doi:10.1002/chem.201501441
(2015)Doi:10.1080/00397919408011330
(1994)
